PRNewswire

PT Mowilex expands beyond its high-viscosity paints to high-quality ready-to-use paints, sustaining its credibility with applicators and homeowners and remaining competitive in the market.

SAN ANTONIO, June 3, 2024 /PRNewswire/ -- Frost & Sullivan recently assessed the paints and coatings industry and, based on its findings, recognizes PT Mowilex with the 2024 Indonesian Company of the Year Award. The company is an industry-leading premium paints and coatings... (continue reading...)

Zespri explores the impact of fruit and vegetable consumption on children's wellbeing in world-first childhood dietary intervention study.

MOUNT MAUNGANUI, New Zealand , June 3, 2024 /PRNewswire/ -- Zespri, the world's leading marketer of kiwifruit, is investing in building knowledge and healthy eating habits among children through its latest feasibility study named the Feel Good Study, exploring the relationship between fruits and vegetables (FV) and children's... (continue reading...)

Agreement builds on existing collaboration between the two companies for the joint development of 2nm node technology

TOKYO, June 3, 2024 /PRNewswire/ -- Rapidus Corporation, a manufacturer of advanced logic semiconductors, and multinational technology company IBM (NYSE: IBM), today announced a joint development partnership aimed at establishing mass production technologies for chiplet packages. Through this agreement, Rapidus will receive packaging technology from ... (continue reading...)

SAN DIEGO, June 3, 2024 /PRNewswire/ -- At Bio International Convention 2024, which is taking place here in San Diego during June 3-6, Fapon Biopharma, an innovator in developing therapeutic antibodies and fusion proteins, has announced an immunocytokine with modified IL-10M fused to anti-PD-1 antibody, codenamed FP008. This fusion protein provides a promising therapeutic strategy for solid tumors refractory to anti-PD-1 therapy. The groundbreaking announcement is a... (continue reading...)

YANTAI, China, June 3, 2024 /PRNewswire/ -- RemeGen Co., Ltd. ("RemeGen" or "the Company") (9995.HK, SHA: 688331), a commercial-stage biotechnology company, presented the results of the first-in-human, single-arm, open-label, multi-center Phase I/II study evaluating RC88 in patients with MSLN-expressing advanced solid tumors on June 3, at the American Society of Clinical Oncology Annual Meeting (ASCO 2024) held in Chicago from May 31-June 4, 2024. The first... (continue reading...)